Methylation validation in urothelial carcinoma cell lines revealed that SPARCL1 methylation levels for all 4 of the CpG sites were significantly higher in J82, BFTC909, and T24 cell lines than in RT4 cell line (Figure 3G). Here, SPARCL1 is linked to urothelial carcinoma.